People diagnosed with recurrent IDH-mutant grade 3 astrocytoma, a rare and aggressive brain cancer, lived roughly 11 months longer when treated with a two-drug combination compared to a single agent, according to results from a 343-patient international Phase 3 trial. The study, known as STELLAR, tested eflornithine added to lomustine against lomustine alone, and its full findings were published in the Journal of Clinical Oncology in December 2025. The survival gain is among the largest reported in a randomized trial for this tumor type, and it arrives as oncologists increasingly rely on molecular markers rather than microscope-based grading to match patients with treatments.
Why the STELLAR survival data demand attention right now
Recurrent anaplastic astrocytoma has had few effective treatment options for decades. Lomustine, a chemotherapy drug approved in the 1970s, has remained a default second-line choice largely because nothing better emerged. The STELLAR trial, listed on ClinicalTrials.gov, was designed to test whether eflornithine, a drug that blocks the enzyme ornithine decarboxylase and disrupts polyamine metabolism in tumor cells, could improve outcomes when paired with lomustine.
What makes the timing significant is a shift in how brain tumors are classified. The World Health Organization overhauled its central nervous system tumor criteria in 2021, splitting what was once a single diagnostic bucket into molecularly distinct categories. Tumors carrying IDH mutations but lacking CDKN2A/B deletions are now classified as grade 3 astrocytoma, while those with CDKN2A/B loss are reclassified as grade 4, a designation that carries a worse prognosis. The STELLAR trial enrolled patients under older criteria, but investigators later reanalyzed the data using the 2021 WHO framework. That reanalysis sharpened the survival signal considerably, raising an important question: did the drug combination work better in this refined group because eflornithine’s mechanism of action is especially effective in tumors with intact CDKN2A, or did the reclassification simply remove the sickest patients from the analysis?
Median survival reached 34.9 months with the combination
Among patients whose tumors met the 2021 WHO definition of IDH-mutant grade 3 astrocytoma, median overall survival was 34.9 months with eflornithine plus lomustine versus 23.5 months with lomustine alone. The hazard ratio was 0.64, meaning the combination reduced the risk of death by 36 percent relative to lomustine alone, with a p-value of 0.0136. The trial also showed gains in progression-free survival as assessed by blinded independent central review.
These results first entered the public record through conference abstracts, including an earlier meeting presentation that reported statistically significant benefits in both overall and progression-free survival for the molecularly defined subgroup. The full peer-reviewed paper, now available through the Journal of Clinical Oncology, provides the complete dataset including adverse-event profiles and patient-level demographics. Orbus Therapeutics, the trial’s sponsor, described the findings as showing “clinically meaningful improvements in a rare brain tumor with high unmet need” in a December 2025 statement.
The biological rationale centers on polyamine metabolism. IDH-mutant gliomas depend heavily on polyamine pathways to sustain cell growth. Eflornithine irreversibly inhibits ornithine decarboxylase, the rate-limiting enzyme in polyamine synthesis. In tumors that retain CDKN2A, this metabolic vulnerability may be more pronounced because the cells lack the additional genetic disruption that drives grade 4 tumors toward alternative survival pathways. The 2021 WHO reclassification, by excluding CDKN2A-deleted cases from the grade 3 category, may have isolated precisely the population most susceptible to this metabolic blockade.
From a clinical standpoint, a median overall survival approaching three years in the recurrent setting is notable. Many patients entering STELLAR had already received surgery, radiation, and temozolomide-based chemotherapy. Historically, survival after recurrence for this group has often been measured in low double-digit months. The 11.4-month median improvement therefore represents not just a statistical win but a potentially meaningful extension of time during which patients can maintain function, pursue additional therapies, or enroll in clinical trials.
Safety profile and quality-of-life considerations
The Journal of Clinical Oncology report indicates that the combination’s toxicity was generally manageable and consistent with the known profiles of each agent. Lomustine is associated with myelosuppression, particularly delayed thrombocytopenia and neutropenia, and those events remained among the most common serious adverse effects in both arms. Eflornithine can cause gastrointestinal symptoms and reversible hearing changes; these were observed but did not lead to disproportionate treatment discontinuations in the combination arm compared with lomustine alone.
Importantly, the trial protocol incorporated dose adjustments and treatment delays to mitigate cumulative hematologic toxicity. Investigators reported that most patients were able to receive multiple cycles of therapy, suggesting that the regimen can be delivered in routine practice settings with appropriate monitoring. While formal quality-of-life instruments were not highlighted in public summaries, the extended progression-free interval in the combination group implies longer periods without radiographic or clinical deterioration, a factor that often translates into preserved neurologic function and independence.
Unanswered questions about subgroup selection and next steps
The strongest caveat is that the most striking survival benefit emerged in a subgroup analysis, not the original primary endpoint population. The STELLAR trial enrolled patients diagnosed under pre-2021 criteria, and the molecular reclassification was performed after the fact. While the statistical significance is encouraging, subgroup analyses carry an inherent risk of identifying patterns that do not hold up in prospective testing. No primary source in the current record confirms whether Orbus Therapeutics plans to seek regulatory approval based on these data, or whether regulators would require a confirmatory trial in a prospectively defined 2021 WHO population.
Several practical gaps remain. The ClinicalTrials.gov registry record has not been updated with final subgroup results or complete adverse-event tables. Patient-level demographics broken down by 2021 WHO molecular subtype are available only in the full Journal of Clinical Oncology paper, and it is not clear from public disclosures whether the 343-patient total reported by Orbus Therapeutics represents all screened participants or only those who met strict eligibility criteria and were randomized. Without a detailed accounting of screen failures and molecular exclusions, it is difficult to estimate how many real-world patients with recurrent IDH-mutant astrocytoma would qualify for this regimen.
There are also open questions about how best to sequence eflornithine and lomustine within the broader treatment landscape. Most patients in STELLAR had previously received temozolomide, and some may have undergone re-resection or other salvage therapies before enrollment. Whether earlier introduction of eflornithine, for example at first recurrence or even in the upfront setting alongside radiation and temozolomide, could yield larger gains remains speculative. No publicly available protocol yet outlines such a trial, and investigators will need to weigh the potential benefits against added toxicity and the risk of exhausting options too early in the disease course.
Implications for patients and clinicians
For now, the STELLAR results are likely to influence discussions at major brain tumor centers and within multidisciplinary tumor boards. In patients with recurrent IDH-mutant grade 3 astrocytoma who retain CDKN2A, the combination of eflornithine and lomustine offers a data-backed alternative to lomustine monotherapy, with a survival advantage that appears both statistically and clinically meaningful. Incorporating routine testing for IDH mutation status and CDKN2A/B deletions at recurrence will be essential if clinicians hope to mirror the trial population and interpret the results appropriately.
Patients and families, meanwhile, may view the findings as a rare source of optimism in a field where incremental gains have been the norm. An additional year of median survival does not equate to cure, and the burden of repeated imaging, clinic visits, and side-effect management remains substantial. But the STELLAR experience reinforces the idea that carefully targeted interventions, grounded in tumor biology and refined by modern classification systems, can move the needle even in challenging diseases like recurrent astrocytoma. As more detailed data emerge and potential regulatory paths clarify, eflornithine plus lomustine is poised to become a central part of that evolving conversation.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
